Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial is bioequivalent and medically equivalent to Pfizer Inc.’s Depo-Provera Injectable Suspension.
The product will be available in the third quarter of FY23. According to IQVIA, the authorized product has a market size of roughly US$ 62 million for the period ending June 2022.
This is the 147 ANDA (including ten tentative approvals) received by Eugia Pharma Speciality Group (EPSG) facilities, which manufacture both oral and sterile specialty pharmaceuticals.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.